Suggested remit: To appraise the clinical and cost effectiveness of belumosudil within its marketing authorisation for treating chronic graft versus host disease after 2 or more therapies.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Invitation to participate
Process STA Standard
ID number 4021

Provisional Schedule

Expected publication 22 November 2023

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Sanofi (belumosudil)
Others NHS England
  Welsh Government
Patient carer groups Anthony Nolan
Professional groups Neonatal and Paediatric Pharmacists Group
  Royal College of Physicians
Comparator companies Novartis Pharmaceuticals UK (mycophenolate mofetil)
  Mallinckrodt Pharmaceuticals
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups National Institute for Health Research


Key events during the development of the guidance:

Date Update
13 September 2023 Committee meeting
13 January 2023 Invitation to participate
13 January 2023 In progress
06 January 2023 Topic selection
06 January 2023 Topic selection. The topic routing was discussed at the Topic Selection Oversight Panel (TSOP) in November 2022. The panel concluded that the topic was suitable for a Technology Appraisal. Please see project documents for further details. The evaluation is expected to begin with an invitation to participate in January 2023 with a first committee meeting in September 2023.
07 November 2022 (14:00) Scoping workshop
09 September 2022 - 07 October 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4021
09 September 2022 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual